Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Christos K Fountzilas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3837-5644; OpenAlex author ID A5033837903, A5158587751. Sources: ClinicalTrials.gov.

Their work

Papers
23 (first author 1, last author 3)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
153
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 4 papers, 1 trial · 2025: 4 papers, 1 trial · 2026: 4 papers, 2 trials

Papers 23

  1. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  2. Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreat… Co-author DOI 10.1200/jco-25-02199↗
  3. Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. Co-author DOI 10.1200/po-25-01088↗
  4. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  5. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. First author DOI 10.1007/s10689-025-00475-7↗
  6. Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma. Co-author DOI 10.1016/j.esmogo.2025.100194↗
  7. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  8. Pancreatic Steatosis as a Risk Factor for Pancreatic Ductal Adenocarcinoma: Pathogenesis and Clinical Implications. Last author DOI 10.14309/ctg.0000000000000832↗
  9. Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.27803↗
  10. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  11. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  12. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323↗
  13. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  14. Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0547↗
  15. Sugar Sweetened and Artificially Sweetened Beverage Consumption and Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.3390/nu15020275↗
  16. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras agai… Co-author DOI 10.1002/ctm2.881↗
  17. Cruciferous vegetable consumption and pancreatic cancer: A case-control study. Co-author DOI 10.1016/j.canep.2021.101924↗
  18. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  19. Physical Inactivity and Pancreatic Cancer Mortality. Co-author DOI 10.1007/s12029-020-00441-9↗
  20. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Last author DOI 10.1158/1078-0432.ccr-19-2078↗
  21. Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Last author DOI 10.3390/cancers11121980↗
  22. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  23. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Co-author DOI 10.1007/s00280-017-3375-9↗

Trials 4

  1. NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial Principal investigator NCT06821997↗
  2. Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT07214298↗
  3. FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Principal investigator NCT06206876↗
  4. Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Principal investigator NCT04870034↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 4 shared papers, 2024–2026 · strength 0.71
  2. Kenan Onel · 2 shared papers, 2025–2026 · strength 0.57
  3. Erik S. Knudsen · 2 shared papers, 2025–2026 · strength 0.57
  4. Agnieszka Katarzyna Witkiewicz · 2 shared papers, 2025–2026 · strength 0.57
  5. Leonid Cherkassky · 2 shared papers, 2024–2026 · strength 0.53
  6. Zev A. Wainberg · 3 shared papers, 2023–2024 · strength 0.50
  7. Dana Backlund Cardin · 4 shared papers, 2019–2026 · strength 0.50
  8. Vincent M. Chung · 4 shared papers, 2019–2026 · strength 0.50
  9. Elena Gabriela Chiorean · 4 shared papers, 2019–2026 · strength 0.50
  10. Kirsten B. Moysich · 3 shared papers, 2020–2023 · strength 0.47
  11. Renuka V. Iyer · 3 shared papers, 2017–2025 · strength 0.45
  12. Zoi Papalamprakopoulou · 1 shared paper, 2025 · strength 0.37
  13. Prasenjit Dey · 1 shared paper, 2025 · strength 0.37
  14. Nathan Bahary · 2 shared papers, 2024 · strength 0.36
  15. Erkut Hasan Borazanci · 2 shared papers, 2024 · strength 0.36
  16. Marcus Smith Noel · 2 shared papers, 2025–2026 · strength 0.36
  17. Davendra P. S. Sohal · 2 shared papers, 2023–2026 · strength 0.33
  18. Vivek U. Nimgaonkar · 2 shared papers, 2023–2026 · strength 0.33
  19. Andrew Eugene Hendifar · 2 shared papers, 2023–2026 · strength 0.33
  20. Eric Andrew Collisson · 2 shared papers, 2023–2026 · strength 0.33
  21. Aatur Dilip Singhi · 2 shared papers, 2023–2026 · strength 0.33
  22. Andrew H. Ko · 3 shared papers, 2019–2026 · strength 0.33
  23. Brian G. Czito · 3 shared papers, 2019–2026 · strength 0.33
  24. Noelle K. LoConte · 3 shared papers, 2019–2026 · strength 0.33
  25. Robert A. Wolff · 3 shared papers, 2019–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.